SOLVD Health’s Risk Test for Opioid Use Disorder Cleared in Europe
SOLVD Health has announced that its genetic test for opioid use disorder has been given CE mark certification.
The test uses a cheek-swab sample to detect 15 genetic variants related to the brain reward pathway in patients that may put them at an increased risk for opioid use disorder. It was previously granted Breakthrough Device designation by the FDA in 2018.
“Healthcare providers can use this personalized risk information to make more informed decisions about the use of oral opioids for acute pain when developing pain management plans for their patients,” SOLVD said.